Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ By Ogkologos - January 8, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer December 1, 2023 Cancer in My Community: Striving to Lead People to Cancer Care... November 22, 2022 What if we count all that still remains? June 11, 2021 Professor Eithne Costello: On the road to early detection November 12, 2021 Load more HOT NEWS No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... What Do You Put In Your Pocket? SIOG 2020: New Research in Caring for and Treating People With...
